How Does Estrogen Support Cardiovascular Health in Midlife?

Does Estrogen Prevent Heart Disease?

No. This is the clearest answer from the randomized evidence. The Women's Health Initiative tested menopausal hormone therapy for prevention of chronic disease, and its results do not support using oral conjugated equine estrogens plus medroxyprogesterone acetate, or conjugated equine estrogens alone after hysterectomy, to prevent cardiovascular disease, dementia or other chronic diseases [3]. The Premarin label still states that estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [1].

Cardiovascular disease is uncommon in premenopausal women and becomes more common after the menopausal transition [7]. But replacing estrogen after menopause has not been shown to prevent heart attacks or strokes. The Menopause Society's 2022 position statement identifies hormone therapy as the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and as preventing bone loss and fracture [4].

What Did the WHI Find?

The WHI estrogen-plus-progestin trial enrolled 16,608 postmenopausal women aged 50 to 79 with a uterus (mean age about 63) and assigned them to conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily or placebo. The trial was stopped early at a mean of 5.2 years. Hazard ratios were 1.29 for coronary heart disease, 1.26 for breast cancer, 1.41 for stroke and 2.13 for pulmonary embolism [2].

The estrogen-alone trial told a more mixed story. The Premarin label reports no overall effect on coronary heart disease events with estrogen-alone, but an increased risk of stroke and deep vein thrombosis [1]. In the 50-59 age subgroup, the label reports a statistically nonsignificant reduction in CHD events among women with less than 10 years since menopause: 8 versus 16 per 10,000 women-years [1]. That is a small absolute difference in a subgroup, not proof of prevention.

Long-term mortality data show no overall difference. In 27,347 women followed over 18 years of cumulative follow-up across both WHI trials, the pooled all-cause mortality hazard ratio was 0.99 (95% CI 0.94-1.03); it was 1.02 with estrogen plus progestin and 0.94 (0.88-1.01) with estrogen alone. Cardiovascular and cancer mortality were not different from placebo [10].

Why Does Timing Change the Risk?

Timing matters for absolute risk, not for turning hormone therapy into a cardiovascular prevention drug. A WHI analysis of the combined trials grouped women by years since menopause. For women less than 10 years past menopause, the hazard ratio for coronary heart disease was 0.76 (95% CI 0.50-1.16); at 10 to 19 years it was 1.10 (0.84-1.45); at 20 or more years it was 1.28 (1.03-1.58), with a significant trend across groups (P=0.02). The estimated absolute excess risk for CHD was -6 per 10,000 person-years within 10 years, 4 per 10,000 at 10 to 19 years, and 17 per 10,000 at 20 or more years [6].

Stroke behaved differently. Overall, hormone therapy increased stroke risk (HR 1.32, 95% CI 1.12-1.56), and that risk did not vary significantly by age or time since menopause [6]. So earlier starting is not associated with lower risk for every outcome.

The Menopause Society summarizes the clinical position this way: for women younger than 60 or within 10 years of menopause onset with no contraindications, the benefit-risk ratio is favorable for bothersome vasomotor symptoms and prevention of bone loss. For women starting more than 10 years from menopause onset or older than 60, the balance appears less favorable because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia [4].

The KEEPS trial tested early initiation directly. It enrolled 727 healthy women aged 42 to 58 who were 6 to 36 months from their last menses and had a coronary artery calcium score below 50. They received oral conjugated equine estrogens 0.45 mg daily, transdermal estradiol 50 mcg daily, each with 200 mg oral progesterone for 12 days per month, or placebo for 48 months. Carotid intima-media thickness increased by a mean of 0.007 mm per year in all groups, and coronary artery calcium progression did not differ significantly. Serious adverse events did not differ by treatment, but the trial was not powered to compare clinical cardiovascular events [11].

Is Early Menopause Linked to Cardiovascular Risk?

Yes, in observational data. A pooled analysis of 301,438 women from 15 observational studies found higher cardiovascular disease risk among women who reached menopause early. Compared with menopause at age 50-51, the hazard ratio for a first nonfatal cardiovascular event was 1.55 (95% CI 1.38-1.73) for menopause before age 40 and 1.30 (1.22-1.39) for menopause at 40-44 [5].

Surgical menopause shows a similar pattern. In a prospective U.S. cohort of 121,700 women aged 30 to 55 followed from 1976 to 1982, women who had bilateral oophorectomy and never used estrogen had a rate ratio for coronary heart disease of 2.2 (95% CI 1.2-4.2) compared with premenopausal women. Estrogen use after oophorectomy was associated with a rate ratio of 0.9 (0.6-1.6), similar to premenopausal women [12]. That is observational data, so it cannot show that estrogen caused the difference.

For women with premature or early menopause, a review notes that the long-term consequences include adverse effects on cognition, mood, cardiovascular, bone and sexual health, and that hormone therapy has been shown to lessen some, but not all, of these risks. Multiple medical societies recommend hormone therapy at least until the natural age of menopause in this group [13].

Oral Versus Transdermal Estrogen: What Changes?

Route matters most clearly for venous thromboembolism. A UK nested case-control study compared 80,396 women with VTE to 391,494 controls. Oral hormone therapy was associated with an adjusted odds ratio of 1.58 (95% CI 1.52-1.64) for VTE. Estrogen-only oral therapy had an OR of 1.40 (1.32-1.48) and combined therapy 1.73 (1.65-1.81). Estradiol had a lower risk than conjugated equine estrogen, and transdermal preparations were not associated with VTE risk [8].

This is an observational finding and does not show that transdermal estrogen prevents clots, heart attacks or strokes in any individual woman. The WHI tested oral conjugated equine estrogens; KEEPS included a transdermal estradiol arm but was not powered to compare clinical cardiovascular events [2][11].

How Does Estrogen Affect Cholesterol?

Estrogen does change lipid markers. A pooled analysis of 248 studies found that all estrogen-alone regimens raised HDL cholesterol and lowered LDL and total cholesterol. Oral estrogens raised triglycerides, while transdermal estradiol lowered triglycerides. Progestogens had little effect on estrogen-induced reductions in LDL and total cholesterol, but the type of progestogen opposed estrogen-induced increases in HDL and triglycerides to different degrees. Across 41 studies of 20 formulations, hormone therapy generally lowered lipoprotein(a) [14].

Those are real marker changes. They have not translated into proven cardiovascular prevention in randomized trials [3]. A lower LDL or higher HDL number is not the same as fewer heart attacks.

Does Progestogen Choice Matter?

The Menopause Society notes that risks differ by whether a progestogen is used, along with type, dose, duration and route [4]. The large WHI combined trial used MPA specifically [2]. In a 30-month study in surgically postmenopausal cynomolgus monkeys fed an atherogenic diet, conjugated equine estrogens alone reduced coronary artery atherosclerosis extent by 72% compared with untreated controls. Adding medroxyprogesterone acetate, or using MPA alone, produced atherosclerosis extent that did not differ from untreated controls [15]. That is animal data and should not be translated directly into human prescribing.

In the UK VTE study, combined oral therapy carried a higher VTE odds ratio than estrogen-only therapy (1.73 vs 1.40). Among combined regimens, the lowest odds were with estradiol plus dydrogesterone (OR 1.18, 95% CI 0.98-1.42) and the highest with conjugated equine estrogens plus MPA (OR 2.10) [8].

What Should a Midlife Woman Take From This?

Estrogen is useful for menopausal symptom relief and bone health, but it is not a heart disease prevention strategy. For a woman with bothersome hot flashes or night sweats who is younger than 60 or within 10 years of menopause and has no contraindications, the Menopause Society considers the benefit-risk ratio favorable for those indications [4].

The Premarin label lists contraindications that include active or past deep vein thrombosis or pulmonary embolism, active or past arterial thromboembolic disease such as stroke or myocardial infarction, and protein C, protein S or antithrombin deficiency or other thrombophilia. It also lists undiagnosed abnormal genital bleeding, breast cancer or a history of it, estrogen-dependent neoplasia, and hepatic impairment or disease [1].

Labeling is also in flux. In November 2025 the FDA asked manufacturers to remove cardiovascular disease, breast cancer and probable dementia statements from the boxed warnings of menopausal hormone therapy products, while keeping the endometrial cancer boxed warning for systemic estrogen-alone products. In February 2026 the FDA approved the first six product label changes [9][16]. For systemic products, the cardiovascular and breast cancer warnings are to stay in the Warnings and Precautions section [9]. Many labels still carry the older boxed warning; the Premarin oral label effective June 4, 2026 still has it [1]. As part of its rationale, the FDA cited randomized studies showing lower all-cause mortality and fewer fractures when hormone therapy starts within 10 years of menopause onset [16][17].